“The primary end point was the efficacy of the mRNA-1273 vaccine in preventing a first occurrence of symptomatic Covid-19 with onset at least 14?days after the second injection in the per-protocol population, among participants who were seronegative at baseline…
A secondary end point was the efficacy of mRNA-1273 in the prevention of severe Covid-19… Additional secondary end points included the efficacy of the vaccine at preventing Covid-19 after a single dose or at preventing Covid-19 according to a secondary (CDC), less restrictive case definition…”
Note: Efficacy against SARS-CoV-2 transmission/infection and COVID-19 mortality were not endpoints (i.e., tested outcomes).
NEJM Group content is protected by copyright. While many NEJM Group content items such as articles, figures, tables, videos, and podcasts are free online, NEJM Group content is for personal, non-commercial use in accordance with copyright law. Reuse of Content Within a Thesis or Dissertation Content (full-text or portions thereof) may be used in print and electronic versions of a dissertation or thesis without formal permission from the Massachusetts Medical Society (MMS), Publisher of the New England Journal of Medicine. The following credit line must be printed along with the copyrighted material: Reproduced with permission from (scientific reference citation), Copyright Massachusetts Medical Society. Source: https://www.nejm.org/about-nejm/permissions